Controversies and problems of volume control and hypertension in haemodialysis

The Lancet

Volumn 388, Issue 10041, 2016, Pages 285-293

  Ok, Ercan ^a   Asci, Gulay ^a   Chazot, Charles ^b   Ozkahya, Mehmet ^a   Mees, Evert J Dorhout ^c  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NephroCare Tassin Charcot   (France)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONTROL STRATEGY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; HYPERVOLEMIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADVERSE EFFECTS; METABOLIC DISORDER; MORTALITY; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RENAL DIALYSIS; WATER-ELECTROLYTE IMBALANCE;

EID: 84975506702     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30389-0     Document Type: Review

References (91)

1. 1 De Jager, DJ, Grootendorst, DC, Jager, KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302 (2009), 1782–1789.
2. 2 K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45:4 suppl 3 (2005), S1–153.
3. 3 Agarwal, R, Nissenson, AR, Batlle, D, Coyne, DW, Trout, JR, Warnock, DG, Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 115 (2003), 291–297.
4. 4 Robinson, BM, Tong, L, Zhang, J, et al. Blood pressure levels and mortality risk among hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 82 (2012), 570–580.
5. 5 Laurent, G, Charra, B, The results of an 8 h thrice weekly haemodialysis schedule. Nephrol Dial Transplant 13:suppl 6 (1998), 125–131.
6. 6 Ozkahya, M, Ok, E, Toz, H, et al. Long-term survival rates in haemodialysis patients treated with strict volume control. Nephrol Dial Transplant 21 (2006), 3506–3513.
7. 7 Foley, RN, Herzog, CA, Collins, AJ, Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62 (2002), 1784–1790.
8. 8 Conlon, PJ, Walshe, JJ, Heinle, SK, Minda, S, Krucoff, M, Schwab, SJ, Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 7 (1996), 2658–2663.
9. 9 Agarwal, R, Blood pressure and mortality among hemodialysis patients. Hypertension 55 (2010), 762–768.
10. 10 Merchant, A, Wald, R, Goldstein, MB, et al. Relationship between different blood pressure measurements and left ventricular mass by cardiac magnetic resonance imaging in end-stage renal disease. J Am Soc Hypertens 9 (2015), 275–284.
11. 11 Koomans, HA, Geers, AB, Mees, EJ, Plasma volume recovery after ultrafiltration in patients with chronic renal failure. Kidney Int 26 (1984), 848–854.
12. 12 Braam, B, Jindal, K, Dorhout Mees, EJ, Hypertension and cardiovascular aspects of dialysis treatment. Clinical management of volume control, 2011, Pabst Science Publishers, Lengerich.
13. 13 Inrig, JK, Patel, UD, Toto, RD, Szczech, LA, Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study. Am J Kidney Dis 54 (2009), 881–890.
14. 14 Chou, KJ, Lee, PT, Chen, CL, et al. Physiological changes during hemodialysis in patients with intradialysis hypertension. Kidney Int 69 (2006), 1833–1838.
15. 15 Cirit, M, Akcicek, F, Terzioglu, E, et al. ‘Paradoxical’ rise in blood pressure during ultrafiltration in dialysis patients. Nephrol Dial Transplant 10 (1995), 1417–1420.
16. 16 Gunal, AI, Karaca, I, Celiker, H, Ilkay, E, Duman, S, Paradoxical rise in blood pressure during ultrafiltration is caused by increased cardiac output. J Nephrol 15 (2002), 42–47.
17. 17 Agarwal, R, Light, RP, Intradialytic hypertension is a marker of volume excess. Nephrol Dial Transplant 25 (2010), 3355–3361.
18. 18 Foley, RN, Parfrey, PS, Harnett, JD, Kent, GM, Murray, DC, Barre, PE, Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49 (1996), 1379–1385.
19. 19 Paoletti, E, Specchia, C, Di Maio, G, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 19 (2004), 1829–1834.
20. 20 Tozawa, M, Iseki, K, Iseki, C, Takishita, S, Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 61 (2002), 717–726.
21. 21 Degoulet, P, Legrain, M, Réach, I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 31 (1982), 103–110.
22. 22 Lynn, KL, McGregor, DO, Moesbergen, T, Buttimore, AL, Inkster, JA, Wells, JE, Hypertension as a determinant of survival for patients treated with home dialysis. Kidney Int 62 (2002), 2281–2287.
23. 23 Mazzuchi, N, Carbonell, E, Fernández-Cean, J, Importance of blood pressure control in hemodialysis patient survival. Kidney Int 58 (2000), 2147–2154.
24. 24 De Lima, JJ, Vieira, ML, Abensur, H, Krieger, EM, Baseline blood pressure and other variables influencing survival on haemodialysis of patients without overt cardiovascular disease. Nephrol Dial Transplant 16 (2001), 793–797.
25. 25 Salem, MM, Bower, J, Hypertension in the hemodialysis population: any relation to one-year survival?. Am J Kidney Dis 28 (1996), 737–740.
26. 26 Salem, MM, Hypertension in the haemodialysis population: any relationship to 2-years survival?. Nephrol Dial Transplant 14 (1999), 125–128.
27. 27 Zager, PG, Nikolic, J, Brown, RH, et al., Medical Directors of Dialysis Clinic, Inc. “U” curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 54 (1998), 561–569.
28. 28 Stidley, CA, Hunt, WC, Tentori, F, et al., Medical Directors of Dialysis Clinic Inc. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 17 (2006), 513–520.
29. 29 Töz, H, Ozkahya, M, Ozerkan, F, Aşçi, G, Ok, E, Improvement in “uremic” cardiomyopathy by persistent ultrafiltration. Hemodial Int 11 (2007), 46–50.
30. 30 Raimann, JG, Williams, C, Gupta, S, et al. Systematic reduction of interdialytic weight gain and posthemodialysis weight lowers systolic and diastolic blood pressure: Preliminary results of a quality improvement project. Nephrol Dial Transplant 30:suppl 3 (2015), ii276–ii297.
31. 31 Levin, NW, Kotanko, P, Eckardt, KU, et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 77 (2010), 273–284.
32. 32 Takahashi, A, Takase, H, Toriyama, T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study. Nephrol Dial Transplant 21 (2006), 2507–2512.
33. 33 Cice, G, Di Benedetto, A, D'Isa, S, et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 56 (2010), 1701–1708.
34. 34 Tai, DJ, Lim, TW, James, MT, Manns, BJ, Tonelli, M, Hemmelgarn, BR, Alberta Kidney Disease Network. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol 5 (2010), 623–630.
35. 35 Heerspink, HJ, Ninomiya, T, Zoungas, S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 373 (2009), 1009–1015.
36. 36 Zannad, F, Kessler, M, Lehert, P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70 (2006), 1318–1324.
37. 37 Iseki, K, Arima, H, Kohagura, K, et al., Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant 28 (2013), 1579–1589.
38. 38 Peters, CD, Kjaergaard, KD, Jensen, JD, et al. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. Kidney Int 86 (2014), 625–637.
39. 39 Lopes, AA, Bragg-Gresham, JL, Ramirez, SP, et al. Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. Nephrol Dial Transplant 24 (2009), 2809–2816.
40. 40 Katzarski, KS, Nisell, J, Randmaa, I, Danielsson, A, Freyschuss, U, Bergström, J, A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. Am J Kidney Dis 30 (1997), 459–465.
41. 41 Vertes, V, Cangiano, JL, Berman, LB, Gould, A, Hypertension in end-stage renal disease. N Engl J Med 280 (1969), 978–981.
42. 42 Curtis, JR, Eastwood, JB, Smith, EK, et al. Maintenance haemodialysis. Q J Med 37 (1969), 49–89.
43. 43 Charra, B, Calemard, E, Ruffet, M, et al. Survival as an index of adequacy of dialysis. Kidney Int 41 (1992), 1286–1291.
44. 44 Ok, E, Asci, G, Toz, H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 28 (2013), 192–202.
45. 45 Charra, B, Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int 11 (2007), 21–31.
46. 46 Kayikcioglu, M, Tumuklu, M, Ozkahya, M, et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant 24 (2009), 956–962.
47. 47 Harnett, JD, Foley, RN, Kent, GM, Barre, PE, Murray, D, Parfrey, PS, Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47 (1995), 884–890.
48. 48 Arneson, TJ, Liu, J, Qiu, Y, Gilbertson, DT, Foley, RN, Collins, AJ, Hospital treatment for fluid overload in the Medicare hemodialysis population. Clin J Am Soc Nephrol 5 (2010), 1054–1063.
49. 49 Ozdogan, O, Kayikcioglu, M, Asci, G, et al. Left atrial volume predicts mortality in low-risk dialysis population on long-term low-salt diet. Am Heart J 159 (2010), 1089–1094.
50. 50 Agarwal, R, Hypervolemia is associated with increased mortality among hemodialysis patients. Hypertension 56 (2010), 512–517.
51. 51 Wizemann, V, Wabel, P, Chamney, P, et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 24 (2009), 1574–1579.
52. 52 Zoccali, C, Torino, C, Tripepi, R, et al., Lung US in CKD Working Group. Pulmonary congestion predicts cardiac events and mortality in ESRD. J Am Soc Nephrol 24 (2013), 639–646.
53. 53 Katzarski, KS, Charra, B, Luik, AJ, et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 14 (1999), 369–375.
54. 54 Saran, R, Bragg-Gresham, JL, Rayner, HC, et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 64 (2003), 254–262.
55. 55 Kalantar-Zadeh, K, Regidor, DL, Kovesdy, CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 119 (2009), 671–679.
56. 56 Scribner, BH, Buri, R, Caner, JE, Hegstrom, R, Burnell, JM, The treatment of chronic uremia by means of intermittent hemodialysis: a preliminary report. Trans Am Soc Artif Intern Organs 6 (1960), 114–122.
57. 57 Guyton, AC, Kidneys and fluids in pressure regulation: small volume but large pressure changes. Hypertension 19:suppl 1 (1992), 12–18.
58. 58 Koomans, HA, Roos, JC, Boer, P, Geyskes, GG, Mees, EJ, Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 4 (1982), 190–197.
59. 59 Guyton, AC, Arterial pressure and hypertension, 1980, WB Saunders Company, London.
60. 60 Converse, RL Jr, Jacobsen, TN, Toto, RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327 (1992), 1912–1918.
61. 61 Sellars, L, Robson, V, Wilkinson, R, Sodium retention and hypertension with short dialysis. BMJ 1 (1979), 520–521.
62. 62 Laurent, G, How to keep the dialysis patients normotensive? What is the secret of Tassin?. Nephrol Dial Transplant, 12, 1997, 1104.
63. 63 Charra, B, Bergström, J, Scribner, BH, Blood pressure control in dialysis patients: importance of the lag phenomenon. Am J Kidney Dis 32 (1998), 720–724.
64. 64 Twardowski, ZJ, Sodium, hypertension, and an explanation of the “lag phenomenon” in hemodialysis patients. Hemodial Int 12 (2008), 412–425.
65. 65 Chazot, C, Charra, B, Laurent, G, et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 10 (1995), 831–837.
66. 66 Ozkahya, M, Ok, E, Cirit, M, et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 13 (1998), 1489–1493.
67. 67 Cirit, M, Ozkahya, M, Cinar, CS, et al. Disappearance of mitral and tricuspid regurgitation in haemodialysis patients after ultrafiltration. Nephrol Dial Transplant 13 (1998), 389–392.
68. 68 Erdem, Y, Arici, M, Altun, B, et al. The relationship between hypertension and salt intake in Turkish population: SALTURK study. Blood Press 19 (2010), 313–318.
69. 69 Tripepi, G, Mattace-Raso, F, Mallamaci, F, et al. Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease. Hypertension 54 (2009), 818–824.
70. 70 Sinha, AD, Light, RP, Agarwal, R, Relative plasma volume monitoring during hemodialysis AIDS the assessment of dry weight. Hypertension 55 (2010), 305–311.
71. 71 Cheriex, EC, Leunissen, KM, Janssen, JH, Mooy, JM, van Hooff, JP, Echography of the inferior vena cava is a simple and reliable tool for estimation of ‘dry weight’ in haemodialysis patients. Nephrol Dial Transplant 4 (1989), 563–568.
72. 72 Charra, B, Laurent, G, Chazot, C, et al. Clinical assessment of dry weight. Nephrol Dial Transplant 11:suppl 2 (1996), 16–19.
73. 73 Jansen, MA, Hart, AA, Korevaar, JC, Dekker, FW, Boeschoten, EW, Krediet, RT, for the NECOSAD Study Group. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 62 (2002), 1046–1053.
74. 74 Burton, JO, Jefferies, HJ, Selby, NM, McIntyre, CW, Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 4 (2009), 914–920.
75. 75 Flythe, JE, Kimmel, SE, Brunelli, SM, Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 79 (2011), 250–257.
76. 76 Agarwal, R, Alborzi, P, Satyan, S, Light, RP, Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 53 (2009), 500–507.
77. 77 Curatola, G, Bolignano, D, Rastelli, S, et al. Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events. J Nephrol 24 (2011), 465–473.
78. 78 Ozkahya, M, Toz, H, Qzerkan, F, et al. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 15 (2002), 655–660.
79. 79 Ozkahya, M, Töz, H, Unsal, A, et al. Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor. Am J Kidney Dis 34 (1999), 218–221.
80. 80 Tomson, CR, Advising dialysis patients to restrict fluid intake without restricting sodium intake is not based on evidence and is a waste of time. Nephrol Dial Transplant 16 (2001), 1538–1542.
81. 81 McCausland, FR, Waikar, SS, Brunelli, SM, Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients. Kidney Int 82 (2012), 204–211.
82. 82 Tuomilehto, J, Jousilahti, P, Rastenyte, D, et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet 357 (2001), 848–851.
83. 83 Cook, NR, Cutler, JA, Obarzanek, E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 334 (2007), 885–888.
84. 84 Penne, EL, Sergeyeva, O, Sodium gradient: a tool to individualize dialysate sodium prescription in chronic hemodialysis patients?. Blood Purif 31 (2011), 86–91.
85. 85 de Paula, FM, Peixoto, AJ, Pinto, LV, Dorigo, D, Patricio, PJ, Santos, SF, Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int 66 (2004), 1232–1238.
86. 86 Santos, SF, Peixoto, AJ, Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008), 522–530.
87. 87 Culleton, BF, Walsh, M, Klarenbach, SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 298 (2007), 1291–1299.
88. 88 Chertow, GM, Levin, NW, Beck, GJ, et al., FHN Trial Group. In-center hemodialysis six times per week versus three times per week. N Engl J Med 363 (2010), 2287–2300.
89. 89 Susantitaphong, P, Koulouridis, I, Balk, EM, Madias, NE, Jaber, BL, Effect of frequent or extended hemodialysis on cardiovascular parameters: a meta-analysis. Am J Kidney Dis 59 (2012), 689–699.
90. 90 Rocco, MV, Lockridge, RS Jr, Beck, GJ, et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 80 (2011), 1080–1091.
91. 91 Kaysen, GA, Greene, T, Larive, B, et al. The effect of frequent hemodialysis on nutrition and body composition: frequent Hemodialysis Network Trial. Kidney Int 82 (2012), 90–99.